Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and Drug Administration’s (FDA) new national priority voucher, positioning it for potentially accelerated approval. The pharmaceutical giant plans to submit its application this quarter, with the FDA set to determine the review timeline. Under the new program, qualifying drugs can receive review periods as short as one to two months, compared to the usual ten to twelve.
The criteria for the voucher program include innovation, addressing unmet medical needs, and supporting U.S. manufacturing—three areas in which Lilly claims strong alignment. The GLP-1 pill demonstrated significant effectiveness in late-stage trials, helping patients lose 12.4% of body weight, and Lilly has invested heavily in domestic production facilities to meet future demand.
The FDA recently announced the first nine recipients of this voucher, including Merck KGaA, Sanofi, and Regeneron, signaling heightened competition in the accelerated drug review space.
Alongside regulatory progress, Lilly reported a major earnings beat, driven by surging international demand for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. Third-quarter earnings reached $7.02 per share, well above analyst expectations of $5.69. Sales of Mounjaro totaled $6.5 billion, while Zepbound brought in $3.6 billion, both surpassing projections.
Lilly raised its full-year profit outlook to between $23.00 and $23.70 per share, up from previous guidance. The company now expects annual revenue between $63 billion and $63.5 billion. Analysts credit strong overseas demand and consistent consumer interest in weight-loss therapies for Lilly’s sustained growth, solidifying its leadership position against rival Novo Nordisk. As the global market for obesity drugs accelerates toward an estimated $150 billion by decade’s end, Eli Lilly continues to dominate the sector with robust innovation and expanding market share.
